Page last updated: 2024-11-04

methylglucoside

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID91576
SCHEMBL ID1228684
MeSH IDM0088167
PubMed CID2108
SCHEMBL ID1430362
SCHEMBL ID19738683
SCHEMBL ID21847893
MeSH IDM0088167

Synonyms (86)

Synonym
d-glucoside, methyl
methylglucoside
25360-07-0
glucoside, methyl, d-
einecs 246-894-8
SCHEMBL1228684
HOVAGTYPODGVJG-UVSYOFPXSA-N
LS-13353
nsc3817
nsc-3817
methyl .beta.-galactoside
.alpha.-d-galactopyranose methyl glycoside
methyl-.beta.-galactoside
.beta.-methyl-d-galactopyranoside
methyl .beta.-d-galactopyranoside, .beta.-d-
nsc33685
nsc33684
.beta.-d-galactopyranoside, methyl
.beta.-d-galactopyranose methyl glycoside
nsc214092
NCIOPEN2_001794
methyl ?-d-mannopyranoside
AC-907/25014385
smr000386958
MLS001049132
methyl d-galactoside
glucopyranoside, .alpha.-d-
nsc102101
nsc-403457
nsc403949
.beta.-d-glucopyranoside, methyl
nsc403457
.beta.-methylglucoside
nsc-403949
nsc1225
.alpha.-methyl mannopyranoside
nsc-1225
mannopyranoside, .alpha.-d-
nsc-163490
nsc163490
nsc-227937
nsc227937
methyl-d-glucoside
mannopyranoside, 1-o-methyl-, alpha-d-
03AFED88-DA24-4BCE-B79F-84CAF2B36351
inchi=1/c7h14o6/c1-12-7-6(11)5(10)4(9)3(2-8)13-7/h3-11h,2h2,1h3
hovagtypodgvjg-uhfffaoysa-
FT-0693585
2-(hydroxymethyl)-6-methoxyoxane-3,4,5-triol
NCGC00246215-02
NCGC00246215-01
AKOS006227638
HMS2268J22
FT-0628704
FT-0628705
FT-0628857
FT-0628855
FT-0628701
FT-0628856
FT-0628867
methyl-.beta.-d-thiogalactoside
methyl .beta.-d-galactopyranoside, methyl, .beta.-d-
HOVAGTYPODGVJG-UHFFFAOYSA-N
galactopyranoside, methyl, .beta.-d-
SCHEMBL1430362
methyl ?-d-galactopyranoside monohydrate
mfcd08692046
1-o-methyl-alpha-d-glucoside hydrate
1-o-methyl-beta-d-glucoside
1-o-methyl-beta-d-galactoside
.beta.-d-altropyranoside, methyl
methyl |a-d-glucoside
methyl |a-d-glucoside hemihydrate
SCHEMBL19738683
SY066776
SY076496
688007-20-7
DTXSID60859172
(d3)methyl a-d-glucoside
SCHEMBL21847893
SB44902
SB45069
methyl-a-d-altropyranoside
SY056715
SY066748
SY112991

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Aminooxyacetic acid, which prevents the formation of the ultimate toxic metabolite by inhibition of beta-lyase, abolished almost completely the toxicity of both compounds."( Isolated proximal tubular cells from rat kidney as an in vitro model for studies on nephrotoxicity. II. Alpha-methylglucose uptake as a sensitive parameter for mechanistic studies of acute toxicity by xenobiotics.
Boogaard, PJ; Mulder, GJ; Nagelkerke, JF, 1989
)
0.28
"Nephrotoxicity is the major adverse effect produced by chronic exposure to cadmium (Cd)."( Nephrotoxicity of CdCl2 and Cd-metallothionein in cultured rat kidney proximal tubules and LLC-PK1 cells.
Klaassen, CD; Liu, J; Liu, Y, 1994
)
0.29

Dosage Studied

ExcerptRelevanceReference
" The time course and dose-response curves of PTH-stimulated cAMP accumulation were studied in dog and rat PTC."( Dog and rat kidney proximal tubule cells in culture: responses to parathyroid hormone.
Kovacs, K; Rao, LG; Yau, CH, 1989
)
0.28
" It is apparent from the dose-response data that up-regulation is not inhibited by irradiation in a simple manner and is not inhibited at the same radiation dose as cell replication."( Role of cell replication in regulation of Na-coupled hexose transport in LLC-PK1 epithelial cells.
Hagan, M; Handler, JS; Moran, A, 1986
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency3.16230.044717.8581100.0000AID485294
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency0.70790.00798.23321,122.0200AID2551
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (15)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (447)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990146 (32.66)18.7374
1990's144 (32.21)18.2507
2000's111 (24.83)29.6817
2010's39 (8.72)24.3611
2020's7 (1.57)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 42.36

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index42.36 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.30 (4.65)
Search Engine Demand Index57.63 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (42.36)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Reviews4 (0.89%)6.00%
Reviews0 (0.00%)6.00%
Case Studies3 (0.67%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other442 (98.44%)84.16%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]